Cellectis abandons CAR-T programs, shifts focus to in vivo gene editing

Cellectis announced it will discontinue its donor-derived CAR‑T programs and redirect its efforts toward in vivo gene‑editing medicines.

The company said the commercial and clinical landscape for blood‑cancer CAR‑T therapies has changed materially, leading it to off‑load its lead programs.

The pivot ends work on several CAR‑T candidates, including an out‑licensed program that had reached Phase 2, and reallocates resources to gene‑editing approaches that have not yet entered human trials.

Investors reacted negatively, with the stock falling as much as 43% in morning trading, leaving shares near all‑time lows around $2.